COVID-19 Vaccines from Pfizer, Moderna Effective in Real World

In real world conditions, Pfizer-BioNTech and Moderna's COVID-19 vaccines are highly effective in preventing infections, reveals a new study by the US Centers for Disease Control and Prevention (CDC).

Following a single dose of either vaccine, the participants' risk of infection with SARS-CoV-2 was reduced by 80 per cent two or more weeks after vaccination.

Mucormycosis (Black Fungal Disease): A Complication of COVID-19
Mucormycosis is spread by spores from the black fungus, Mycormycetes. It mainly affects people with a weak immune system and attacks the lungs and other organs of the body. It is also known as Black Fungal Disease.

‘Results showed that following the second dose of COVID-19 vaccine, risk of infection was reduced by 90 per cent two or more weeks after vaccination. ’

Tweet it Now

The study looked at the effectiveness of Pfizer-BioNTech and Moderna mRNA vaccines in preventing SARS-CoV-2 infections among nearly 4,000 participants in six US states over a 13-week period from December 14, 2020 to March 13, 2021.

It takes about two weeks following each dose of vaccine for the body to produce antibodies that protect against infection.

As a result, people are considered "partially vaccinated" two weeks after their first dose of mRNA (Messenger RNA) vaccine and "fully vaccinated" two weeks after their second dose.

COVID-19 Vaccination in India: Issues and Challenges
India’s COVID-19 vaccination program has been launched. It currently uses the vaccines Covishield and Covaxin. There are some issues and challenges that need to be overcome in order to vaccinate all Indians.

These new vaccine effectiveness findings are consistent with those from phase-3 clinical trials conducted with the vaccines before they received Emergency Use Authorisations from the US Food and Drug Administration (FDA).

Those clinical trials evaluated vaccine efficacy against Covid-19 disease, while this study evaluated vaccine effectiveness against infection, including infections that did not result in symptoms.

COVID-19 Vaccines Show Limitations on Viral Vectors
Limited viral vector capacities are faced by AstraZeneca’s and Johnson & Johnson’s (J&J) latest wave of COVID-19 vaccines.

"This study shows that our national vaccination efforts are working. The authorised mRNA Covid-19 vaccines provided early, substantial real-world protection against infection for our nation's health care personnel, first responders, and other frontline essential workers," CDC Director Rochelle Walensky, said in a statement.

This study also provided positive news about partial (one-dose) vaccination.

Is COVID-19 Vaccine Safe in Kidney Transplant Recipients?
Current guidance from multiple professional organizations recommend vaccination for all eligible organ transplant recipients. But more studies are needed to characterize the safety, immunogenicity, and ultimately, efficacy of SARS-CoV-2 vaccines for transplant recipients.

The estimate of 80 per cent effectiveness in this study is consistent with other recent studies following the first dose of Pfizer-BioNTech vaccine among health care providers.

Studies conducted in the UK and Israel showed that one dose was about 70 per cent and 60 per cent effective, respectively, against SARS-CoV-2 infection.

The current results provide reassurance that people start to develop protection from the vaccine two weeks after their first dose.

The greatest protection was seen among those who had received both recommended doses of the vaccine.

Source-IANS